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Abstract: In April 2010, the European Medicines Agency Committee for Medicinal Products 
for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4   inhibitor, 
for the “maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV1 
postbronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients 
with a history of frequent exacerbations as add-on to bronchodilator treatment”. This   decision 
was based, in part, on the results of several large, international, multicenter, randomized, 
  placebo-controlled trials of either six or 12 months’ duration that had been undertaken in COPD 
patients. Roflumilast 500 µg daily improved lung function and reduced exacerbations in patients 
with more severe COPD, especially those with chronic bronchitis, frequent exacerbations, or 
who required frequent rescue inhaler therapy in the placebo-controlled trials. It also improved 
lung function and reduced exacerbations in patients with moderately severe COPD treated with 
salmeterol or tiotropium. Advantages of roflumilast over inhaler therapy are that it is an oral tablet 
and only needs to be taken once daily. While taking roflumilast, the most common adverse effects 
patients experienced were gastrointestinal upset and headache. Weight loss, averaging 2.2 kg, 
occurred in patients treated with roflumilast. Patients taking roflumilast were more likely to drop 
out of the trials than patients in the control groups. Patients who discontinued therapy usually 
did so during the first few weeks and were more likely to have experienced   gastrointestinal side 
effects. Roflumilast is the first selective phosphodiesterase 4 inhibitor and will offer physicians 
another treatment option for patients with more severe COPD.
Keywords: roflumilast, phosphodiesterase 4 inhibitor, chronic obstructive pulmonary disease, 
exacerbation
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth most common cause 
of death in the US and is also a major cause of morbidity.1,2 Lung parenchymal 
  destruction, ie, emphysema, and obstructive bronchiolitis are the typical pathologic 
changes in COPD and are characterized functionally by progressive airway obstruc-
tion.1   Inflammatory changes and mucus gland hyperplasia in the larger airways may 
also occur, and are accompanied by chronic cough and mucus hypersecretion. The 
clinical course of COPD is punctuated by exacerbations, periods of deterioration 
characterized by worsening dyspnea, and increases in cough, sputum volume, and 
sputum purulence usually associated with respiratory tract infection. Acute exacerba-
tions of COPD are accompanied by acute deterioration in lung function and   worsening 
disability.3 More frequent exacerbations are associated with a more rapid decline 
in lung   function.3 Exacerbations that are severe enough to require hospitalization Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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are particularly   ominous because they are associated with 
  significant inhospital   mortality, and discharged patients 
have a 9% mortality rate within 30 days, and 28% are dead 
within one year.4,5
Inflammation in COPD
CD68+ macrophages and CD8+ T lymphocytes are the 
  predominant inflammatory cells in COPD, with polymorphs 
increasing during acute exacerbations.6 The severity of 
  inflammation in the small airways and lung parenchyma 
increases with worsening COPD.6 These alterations con-
tribute to airways thickening, resulting in luminal narrow-
ing, and parenchymal destruction diminishes elastic recoil. 
Along with mucus hypersecretion, these abnormalities 
contribute to airways obstruction and to the reduction in 
airflow.6 In COPD, blood levels of the proinflammatory 
cytokines   interleukin (IL)-1β, IL-6, and tumor necrosis 
factor-α (TNFα) are increased.7 The level of IL-32, a recently 
described cytokine expressed in bronchial epithelium, mac-
rophages, and CD8+ cells, which promotes TNFα, IL-8, and 
CXCL2 expression, is also elevated and correlates with the 
reduction in forced   expiratory volume in one second (FEV1) 
in COPD patients.7
COPD is associated with a variety of comorbidities and 
extrapulmonary symptoms.8,9 It has been suggested that the 
association between COPD and these other conditions is due to 
the inflammatory process extending   systemically. Leukocyte 
counts and blood levels of C-reactive   protein, fibrinogen, and 
TNFα are higher in COPD patients   compared with matched 
controls.8 Systemic inflammation is   associated with, and 
appears to be a risk factor for, a variety of   symptoms and con-
ditions including weight loss, muscle wasting,   atherosclerosis, 
malignancy, osteoporosis, diabetes, and anemia.1,8,9
Treatment of inflammation  
in COPD
Although generally effective in asthma, inhaled   corticosteroids 
(ICSs) provide relatively modest benefit in COPD.1,8 The pre-
dominance of CD68+ macrophages, CD8+ T lymphocytes, and 
neutrophils, rather than the more corticosteroid-responsive 
eosinophils and CD4+ T lymphocytes present in asthma, 
contribute to the relative resistance to corticosteroids seen 
in COPD.10 Although smoking cessation interventions and 
bronchodilators provide symptomatic relief, there are clear 
unmet clinical needs for patients with COPD. These include 
effective disease-modifying pharmacotherapies that target 
the inflammation and so arrest the relentless decline in lung 
function and reduce the frequency of exacerbations.
One novel class of compounds that may deliver 
  therapeutic benefit in COPD are phosphodiesterase (PDE) 
4 inhibitors. PDE is a generic term that describes a large 
superfamily of enzymes that catalyze the breakdown of 
cyclic adenosine-3’,5’-monophosphate (cAMP) and/or cyclic 
guanosine-3’,5’-monophosphate (cGMP) to their respective 
inactive nucleotide 5’-monophosphates.11 Eleven distinct 
PDE families have been identified,11 although most of the 
anti-inflammatory activity is believed to result from the 
inhibition of PDE4, for which there is clinical precedent.12 
Indeed, theophylline is a weak, nonselective PDE   inhibitor 
(see below) and has been used in clinical practice as a 
  bronchodilator for more than 70 years. More recently, it has 
been reported that theophylline has immunomodulatory and 
anti-inflammatory activities in asthma and COPD at doses 
lower than those required to produce bronchodilation.13–19 
Although mechanisms of action other than PDE4 inhibition 
have been hypothesized to account for the anti-  inflammatory 
activity of theophylline,20 it seems more likely that its 
clinical activity reflects the concurrent (albeit modest) 
inhibition of multiple PDEs in target tissues, resulting in 
additive or even synergistic effects that combine to suppress 
inflammation.21
Unfortunately, theophylline has a narrow therapeutic 
margin, a poor adverse effect profile, and a proclivity to 
interact adversely with other drugs via competition with 
various cytochrome (CYP) 450 metabolizing enzymes, 
which severely limits its widespread clinical utility. In 
  contrast, nonxanthine-based compounds that selectively 
inhibit PDE4 do not share these limitations of theophyl-
line, and have undergone extensive preclinical and clinical 
evaluation.12,21,22 The most advanced compound within this 
class is the   benzamide, roflumilast (see Figure 1), which is 
being developed jointly by Nycomed (Zurich, Switzerland, 
formerly Altana) in Europe and the Forest Research Institute 
in the US (ownership transferred from Nycomed in December 
2009) for the treatment of COPD.
Chemistry
The IUPAC name for roflumilast is 3-(cyclopropylmethoxy)-
N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benz-
amide; CAS 162401-32-3). The trade name is Daxas® and 
research codes are APTA 2217, B9302–107, BY 217, and 
BYK 20869.23 Roflumilast is synthesized in five steps from 
3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde.24 The 
compound is achiral, and appears as a white crystalline solid 
with a melting point, parent molecular weight, and empirical 
formula of 158°C, 403.22, and C17H14Cl2F2N2O3, respectively. Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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The compound is sparingly soluble in aqueous media but is 
soluble in organic solvents, including dimethylsulfoxide. The 
structure of roflumilast docked in the catalytic sites of PDE4 
isoforms has been solved by x-ray co-crystallography.25
Biochemistry and enzymology
Roflumilast and its primary metabolite, roflumilast N-oxide, 
are potent and competitive inhibitors of PDE4.26 However, 
PDE4 is not a single enzyme and, in humans, in excess of 
50 different variants have been identified that are encoded 
by four genes, PDE4A, PDE4B, PDE4C, and PDE4D.27 
These enzymes have absolute specificity for cAMP and are 
expressed across almost all immune and proinflammatory 
cells that are believed to contribute to disease pathogenesis.12 
The finding that elevation of cAMP within the lung exerts 
anti-inflammatory activity in a variety of preclinical models 
fuelled the idea that PDE4 could be exploited to therapeutic 
advantage in COPD with small molecule inhibitors, such as 
roflumilast.26
Using PDE4 isolated from human neutrophils, which 
  contains a mixture of different PDE4s, roflumilast and 
roflumilast N-oxide have IC50 values of 800 pM and 
2 nM, respectively.26 However, neither of these   compounds 
  discriminate between PDE4 gene variants, and it is 
  possible21 that this lack of subtype selectivity contributes 
to its improved therapeutic ratio compared with several of 
its predecessors. Indeed, cilomilast and a PDE4 inhibitor 
from   Purdue-Frederick, V-11294A, preferentially inhibit 
(by 10- and 30-fold, respectively) PDE4D,28,29 which has been 
linked with gastrointestinal (GI) events of concern that are 
often associated with this class of drugs.21,30,31 Both of these 
compounds were discontinued from development because of 
unfavorable adverse effect profiles and/or lack of efficacy.32 
Both roflumilast and its N-oxide are highly selective PDE4 
inhibitors, and are essentially inactive against PDEs 1, 2, 3, 
5, and 7 at concentrations up to 10 µM.26
Pharmacodynamics of roflumilast: 
Preclinical and clinical data
The rationale for developing selective PDE4 inhibitors is 
based on three critical findings: PDE4 regulates cAMP 
degradation in most immune and proinflammatory cells; 
in cell-based systems, PDE4 inhibitors of varied structural 
classes suppress a plethora of responses that are considered 
to be proinflammatory; and PDE4 inhibitors are efficacious 
in preclinical animal models that attempt to reproduce spe-
cific facets of COPD pathobiology.12,33,34 If these findings 
are confirmed in humans, PDE4 inhibitors could provide a 
potential disease-modifying therapy in COPD.35
With the exception of the platelet, all immune and proin-
flammatory cells express PDE4.12 PDE4 variants are also 
abundant in structural cells including airway smooth muscle, 
epithelial cells, and fibroblasts.38 Without exception, each of 
these cell types coexpress multiple PDE4 variants derived 
from PDE4A, PDE4B, and PDE4D12 and, currently, the 
isoform(s) that must be inhibited for the anti-inflammatory 
actions of PDE4 inhibitors to be realized is largely unknown. 
Nevertheless, there are considerable in vitro data describing 
the inhibitory effect of the nonselective PDE4 inhibitor, 
roflumilast, on a variety of proinflammatory responses.26,37,38 
  Similarly, in preclinical animal models that reproduce specific 
components of COPD, roflumilast is   efficacious,   suggesting 
that it might be disease-modifying.39–48 For example, in a 
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chronically cigarette-exposed murine model, roflumilast 
significantly reduced the characteristic increase in pulmonary 
neutrophil and macrophage burden and also increased IL-10, 
although goblet cell metaplasia was unaffected.41 Roflumilast 
also prevented the development of experimental emphysema 
in the same cigarette   smoke-exposed murine model.42 In 
another study, using cigarette smoke-exposed guinea pigs, 
roflumilast reduced the numbers of neutrophils,   eosinophils, 
and lymphocytes, as well as protein concentration, in 
bronchoalveolar lavage fluid, whereas methylprednisolone 
only attenuated the eosinophilia.43 There are also in vitro 
data supporting the idea that PDE4 inhibitors, including 
roflumilast and roflumilast N-oxide, may alleviate airway 
remodeling.44–46 Collectively, therefore, this class of drugs 
may exert multiple beneficial effects that combine to arrest 
the progressive decline in lung function that is a defining 
characteristic of COPD.
Despite PDE4 inhibitors being in development for 
more than 20 years, their mechanism(s) of action has not, 
unequivocally, been established. In animals, roflumilast 
does not protect against bronchoconstriction induced by 
leukotriene D4 and 5-hydroxytryptamine.47,48 Similarly, there 
is no evidence that PDE4 inhibitors cause bronchodilation 
in human COPD.49 Thus, an anti-inflammatory effect rather 
than a reduction in airway smooth muscle tone may account 
for the clinical efficacy of this and other PDE4 inhibitors. 
Unfortunately, there are few studies that have examined the 
potential anti-inflammatory effects of roflumilast in humans 
and, therefore, the available data are limited and inconclusive. 
In a double-blind, crossover, placebo-controlled study of four 
weeks’ duration involving 38 patients with COPD (mean post-
bronchodilator FEV1 61% predicted), oral roflumilast 500 µg 
daily reduced the absolute number of neutrophils, eosinophils, 
and lymphocytes in induced sputum by 36%, 50%, and 35%, 
respectively, relative to placebo by the end of the study.50 
Significant reductions in eosinophil cationic protein, IL-8, 
neutrophil elastase, and α2-macroglobulin, a marker of micro-
vascular leak, were also reported.50 The ex vivo generation of 
TNFα induced by lipopolysaccharide (LPS) in whole blood, a 
biomarker of systemic inflammation, was reduced by 10.4%. 
These effects on inflammatory indices were accompanied by 
significant improvements in pre- and postbronchodilator FEV1 
(mean change 80 mL and 69 mL, respectively) compared 
with placebo. A concern with these data is that the statisti-
cal significance for most   inflammatory endpoint measures 
was driven by placebo and this may have overestimated the 
magnitude of the anti-inflammatory effect produced. Thus, 
at the end of the study, the absolute number of neutrophils 
and eosinophils were increased by   approximately 20%–40% 
in the placebo arm relative to   baseline.50 Similar effects were 
also seen for neutrophil elastase and α2-macroglobulin. The 
mechanism responsible for this rapid apparent “deterioration” 
in   inflammatory status after placebo is unclear.
Despite difficulties interpreting these results, other stud-
ies with roflumilast and with the PDE4 inhibitors, cilomilast 
and Bay 19-8004, are consistent with these drugs having 
anti-inflammatory activity in airway diseases. Thus, roflumi-
last significantly decreased neutrophils in the BAL fluid of 
healthy subjects following segmental challenge with LPS51 
and, in a separate investigation, reduced LPS-induced TNFα 
generation ex vivo.52 Cilomilast, given 15 mg twice daily for 
12 weeks, significantly reduced the numbers of subepithelial 
CD8+ T lymphocytes and CD68+ macrophages in bronchial 
biopsies in COPD patients.53 Finally, Bay 19-8004 reduced 
levels of albumin and eosinophil cationic protein in sputum 
samples obtained from patients with COPD.54
Pharmacokinetics of roflumilast  
and roflumilast N-oxide
The absorption, distribution, metabolism, and excre-
tion of roflumilast delivered by the oral route have 
been  examined  in  several  populations  including 
healthy adults, adolescents, and children,55–57 as well as 
in patients with COPD (see www.fda.gov/downloads/
AdvisoryCommittees/  CommitteesMeetingMaterials/Drugs/
Pulmonary-Allergy DrugsAdvisoryCommittee/UCM207377.
pdf). In an open, randomized, two-period crossover study 
involving 12 healthy, fasted, white adult subjects, the 
absorption of roflumilast, administered orally in two 250 µg 
immediate-release tablets, is rapid and complete, with the 
time to peak plasma concentration (Tmax) being reached 
after approximately one hour.55 Roflumilast given orally is 
highly bioavailable (F = 0.79), binds extensively (98.9%) 
to plasma proteins, achieves steady-state levels within four 
days of once-daily dosing, has an elimination half-life (t1/2) 
of between seven and 25 hours (mean about 17 hours) and 
is subject to negligible first-pass hepatic metabolism.55–58 
The clearance (Cl) and volume of distribution (Vd) were 
13 L/hour and 2.92 L/kg, respectively, after a single intrave-
nous dose (120 µg) of roflumilast in healthy adult subjects, 
indicating pronounced distribution in tissues.59 In patients 
with COPD, exposure to roflumilast estimated from the 
area under the concentration-time curve (AUC) up to nine 
hours and the maximum observed plasma   concentration 
(Cmax) was 60% and 6% higher, respectively, when compared 
with normal healthy individuals (www.fda.gov/downloads/Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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AdvisoryCommittees/  CommitteesMeetingMaterials/
Drugs/Pulmonary-  AllergyDrugsAdvisoryCommittee/
UCM207377.pdf).
An open, randomized, two-period, two-sequence,   crossover 
study established that oral ingestion (both single and repeat 
doses) of roflumilast (250 µg and 500 µg)   provides dose-pro-
portional systemic exposure with no difference between the 
single and repeat dose regimens. Similar dose proportionality 
data also were observed for roflumilast N-oxide indicating that 
both compounds display linear pharmacokinetics.59
In humans, the metabolism of roflumilast is extensive, 
involving both Phase I (CYP P450) and Phase II (conjugation) 
reactions, with unchanged drug in urine accounting for less 
than 1% of the administered oral dose. The major metabolic 
pathway for roflumilast elimination after oral administration 
is pyridine N-oxidation with the formation of roflumilast 
N-oxide (see Figure). This process is catalyzed primarily by 
the mixed function oxidases, CYP3A4 and CYP1A2. The 
pharmacokinetics of roflumilast N-oxide are distinct from 
the parent compound. The Tmax is between four hours and 
12 hours, and the Cmax is typically 1- to 2-fold higher.55,58,60,61 
Steady-state plasma levels of roflumilast N-oxide are usually 
achieved within six days of once-daily oral administration 
and the elimination t1/2 is approximately 27 hours, which 
is significantly prolonged relative to the parent compound. 
Roflumilast N-oxide is also highly bound (97%) to plasma 
proteins. Finally, total systemic exposure, estimated from the 
AUC, exceeds that of roflumilast by about 10-fold.59 Taken 
together, these data indicate that the N-oxide metabolite 
accounts for about 90% of the biologic action of roflumilast 
and produces long-lasting, competitive PDE4 inhibition over 
24 hours, making once-daily roflumilast administration a real-
istic treatment regimen. Roflumilast N-oxide is O-  dealkylated 
primarily by CYP3A4, with a small   contribution by CYP2C19 
and extrahepatic CYP1A, glucuronidated, and eliminated via 
the kidney (see Figure).61
Clinical trials of roflumilast  
in COPD
Outcome measures of efficacy in the roflumilast clinical 
development program have been evaluated in several inter-
national, prospective, randomized, double-blind, placebo-
controlled trials involving over 9000 patients with COPD.
ReCORD
The first large clinical trial involved 1411 patients with mod-
erately severe disease (mean post-bronchodilator FEV1 1.5 L, 
54% predicted) with a lack of reversibility to 400 µg albuterol 
and compared the effect of daily treatment with roflumilast 
250 µg or 500 µg for 24 weeks with placebo62 (Table 1). The 
only other respiratory medications allowed during the study 
were short-acting β2-agonists (SABAs) and short-acting 
anticholinergics (SAACs). Approximately a quarter of the 
patients were treated with xanthines, 20% with ICSs, and 15% 
with long-acting β2 agonists (LABAs) prior to study entry. 
RECORD (M2-107) was initiated prior to the marketing of 
tiotropium.62 There were two primary outcome measures, ie, 
the change from baseline in post-bronchodilator FEV1 and 
the St George’s respiratory questionnaire score (SGRQ). At 
the end of the study, roflumilast-treated patients experienced 
greater improvements in postbronchodilator FEV1 (74 mL 
and 97 mL for the 250 µg and 500 µg dose, respectively) and 
health-related quality of life, although the difference from 
baseline did not reach the clinically significant threshold of 
-4 units (Table 2). In addition, exacerbations, primarily of 
mild intensity, were decreased but adverse events were similar 
in the two groups.62 More patients discontinued treatment in 
the roflumilast arms than in the placebo arm. COPD exacer-
bations were the most common adverse effects, followed by 
nasopharyngitis, diarrhea, upper respiratory tract infections, 
and nausea, in descending order of frequency.62
RATiO and OPUS
In two subsequent identical studies, (RATIO, M2-112; 
NCT00430729) and (OPUS, M2-111; NCT00076089), the 
effects of daily roflumilast 500 µg for 12 months were com-
pared with placebo in 1513 patients and 1173 patients with 
more severe COPD.64 In RATIO (mean post-bronchodilator 
FEV1 1.0 L, 41% predicted) 65% of subjects were taking 
ICSs prior to the study and were allowed to continue this 
medication at a steady dose (Table 1). Forty-five percent 
of the patients were taking LABAs and 5% were taking 
tiotropium which were discontinued prior to the study.63 
All participants were allowed SABAs for rescue. The pri-
mary outcome measures were the change from baseline in 
postbronchodilator FEV1 (as in RECORD) and the number 
of moderate or severe exacerbations per patient per year. 
At 12 months, mean   postbronchodilator FEV1 had increased 
by 39 mL   compared with the placebo group but the exacerba-
tion rate was unchanged with roflumilast treatment,63 possibly 
because it was too low for a statistically significant difference 
to be detected (Table 2). However, in a post hoc analysis of a 
subgroup of patients with GOLD stage IV disease, roflumilast 
significantly reduced exacerbation frequency.63 Roflumilast 
did not significantly improve the SGRQ, which was used as 
a secondary outcome, in either patient population.63Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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The results of the OPUS study have not yet been pub-
lished. However, because roflumilast failed to reduce the 
frequency of exacerbations in RATIO, a pooled analysis of the 
RATIO and OPUS datasets has been performed to increase 
the statistical power.64 In this combined group of 2686 
patients (mean postbronchodilator FEV1 39% predicted), 
roflumilast significantly reduced exacerbation frequency by 
13% relative to placebo. This effect was most pronounced in 
those patients with a diagnosis of chronic bronchitis (24% 
reduction) indicating that this phenotype of COPD may 
benefit most from the anti-inflammatory actions of PDE4 
inhibition.
AURA and HeRMeS
Based on the post hoc analysis in RATIO, in which the exac-
erbation rate was less in roflumilast-treated patients with 
GOLD Stage IV disease,63 two identically designed studies 
(AURA [M2-124; NCT00297102] and HERMES [M2-125; 
NCT00297115]) involving 3096 patients with chronic bron-
chitis (mean postbronchodilator FEV1 1.1 L, 36% of predicted) 
compared the effect of daily roflumilast 500 µg for 12 months 
with that of placebo (Table 1). Inclusion in the trial required 
all enrollees to have had experienced at least one exacerba-
tion serious enough to require systemic corticosteroids and/
or hospitalization in the previous year.65 All patients were 
allowed to continue their SABAs, SAACs, and/or LABAs, 
but had to discontinue LAACs and ICSs. On entry, 42% of 
the patients were treated with an ICS and 50% with a LABA. 
The primary outcome measures were change from baseline in 
prebronchodilator FEV1 (in contrast with postbronchodilator 
FEV1 in RATIO) and rate of moderate or severe acute 
  exacerbations. The use of prebronchodilator FEV1 as an 
outcome measure has been developed to assess the effi-
cacy of nonbronchodilators and is recommended by the 
FDA in clinical trials of COPD (see: http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInform
ation/  Guidances/ucm071575.pdf). In this highly selected 
group, patients experienced an improvement in pre- and 
postbronchodilator FEV1 (48 mL and 55 mL, respectively, 
for the pooled data); a reduction in the exacerbation rate 
was also noted (Table 2). Compared with the placebo arm, 
the reduction in moderate or severe   exacerbations was 
17% in the roflumilast-treated patients.65 Of the secondary 
outcome measures, there were small statistically, but not 
clinically, significant improvements in transition dyspnea 
index scores for the roflumilast-treated patients, although 
there was no difference in the health utility assessment 
tool, ie, the Euroquol-5 dimension total score, between 
the roflumilast-treated and placebo groups. Mortality was 
similar in the two study arms. C-reactive protein concen-
tration was used as a marker of systemic inflammation but 
was not different in the roflumilast and placebo groups. 
Roflumilast-treated patients experienced more adverse 
events including weight loss, which averaged 2.2 kg, 
compared with the placebo arm. To summarize, COPD 
patients with more severe airway   obstruction, GOLD stage 
IV disease, those with chronic bronchitis, and those who 
had at least one exacerbation in the previous year, experi-
enced improvement in pre- and postbronchodilator FEV1 
and a reduction in moderate and severe exacerbations, and 
these improvements were independent of smoking status 
or LABA use.65
eOS and HeLiOS
A combination of an ICS and a LABA has been shown to 
be more effective than either class of drug individually at 
improving flow rates and health status, and reducing COPD 
exacerbations.66 Despite the benefits from combination ther-
apy in COPD, treatment has not been shown to   statistically 
decrease mortality.66,67 Moreover, there are concerns about 
adverse effects, including pneumonia, cataracts, glaucoma, 
and reductions in bone density in ICS-treated patients. Two 
Table 1 Patient demographics in the large, randomized roflumilast treatment trials
Rabe 200562 Calverley 200763 Calverley 200965 Fabbri 200968
Salmeterol Tiotropium
Number randomized 1411 1513 3096 933 743
Mean age (years) 64 65 64 65 64
% male 74 76 75 66 72
Smoking history (pack years) 43 44 48 43 43
Current smokers (%) 46 37 41 39 40
Fev1 prebronchodilator 1.4 1.0 1.0 1.4 1.5
Fev1 (% predicted) 54 37 33 52 53
Notes: Data include number of patients randomized in each trial, mean age in years of patients in each trial, percentage of male patients, average smoking history in pack years 
(one pack year = one pack/day for one year), percentage of current smokers, mean prebronchodilator Fev1, and mean Fev1 as a percentage of the predicted value. 
Abbreviation: Fev1, forced expiratory volume in one second.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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trials comparing the effects of roflumilast with placebo 
added to long-acting bronchodilators for 24 weeks, one 
with   salmeterol (EOS M2-127; NCT00313209) and one 
with tiotropium (HELIOS M2-128; NCT00424268), were 
recently   reported.68 The COPD patients in this report had 
milder obstruction (mean postbronchodilator FEV1 1.5–1.6 
L, 55%–56% of predicted) than those in the AURA and 
HERMES trials (mean postbronchodilator FEV1 1.1 L, 36% 
predicted, Table 1).65 In the salmeterol study, although chronic 
bronchitis was not a prerequisite, 79% of patients had chronic 
cough and sputum production.68 Chronic bronchitis and the 
use of a minimum of 28 puffs of rescue inhaler per week were 
prerequisites for the tiotropium study.68 Similar to the earlier 
report,65 more patients dropped out of the roflumilast study 
arms whether they were treated with salmeterol or tiotropium. 
The primary outcome measure was change from baseline 
in prebronchodilator FEV1. In both trials with long-acting 
bronchodilators, pre- and postbronchodilator FEV1 improved 
in patients treated with roflumilast.68 In the EOS trial, pre- 
and postbronchodilator FEV1 were greater in those patients 
given roflumilast plus salmeterol when compared with 
patients taking salmeterol as monotherapy, and this effect 
was similar in magnitude to the increase in postbronchodila-
tor FEV1 reported with the addition of ICS to salmeterol in 
other studies.66,69 Similarly, in the tiotropium study (HELIOS) 
roflumilast improved prebronchodilator FEV1 by 80 mL when 
compared with patients using the LAAC alone (Table 2).68 
In the salmeterol trial, the time to first moderate or severe 
exacerbation, and the proportion of patients experiencing 
an exacerbation, were better in the roflumilast arm. In the 
tiotropium study, median time to any exacerbation and the 
proportion of patients experiencing any exacerbation were 
decreased in the roflumilast study arm.68
Pending trials
The OPUS trial has been completed and a full report is 
expected in 2010.64 As stated above, this study is a replica 
of RATIO and was designed to evaluate the efficacy of 
roflumilast on exacerbation rate and health-related quality of 
life, and on the economic impact of managing patients with 
COPD (see: http://clinicaltrials.gov/ct2/show/NCT0007608
9?term=roflumilast&rank=7).
There is good evidence that FEV1 alone may have limita-
tions as a clinical outcome measure of efficacy.70 As an alterna-
tive, it has been advocated that static or dynamic lung volume 
measurements may provide more instructive information 
pertaining to the impairment of lung function, especially 
in subjects who are poorly reversible.71 The HERO study 
(M2-121) was designed to evaluate the effect of   roflumilast 
on air trapping and measures of hyperinflation in subjects 
with COPD. The trial has been completed but not published 
(http://clinicaltrials.gov/ct2/show/NCT00108823?term=rofl
umilast&rank=20).
Safety and tolerability
In the roflumilast clinical development program, patient 
withdrawals were similar in those patients who received 
roflumilast when compared with placebo, although more 
patients taking roflumilast withdrew within the first 12 weeks 
of treatment.62–66,68 The most common reasons for with-
drawal in the roflumilast group were GI adverse events or 
Table 2 Patient outcomes in the roflumilast treatment trials
Rabe 200562 Calverley 200763 Calverley 200965 Fabbri 200968
500 μg Salmeterol Tiotropium
Pre-Fev1(mL) 88 36 48 49 80
Post-Fev1 (mL) 97 39 55 60 81
SGRQ -1.7 +0.3
Dropouts (%) 22/11 29/22 33/31 23/18 17/10
exacerbation rate 0.28/0.30 0.86/0.92 1.14/1.37 18/11 11/16
weight loss (kg) N/A N/A 2.2 2.2 2.1
Diarrhea (%) 9/2 9/3 8/3 8/3 9/1
Nausea (%) 5/1 5/1 4/2 5/1 3/1
Headache (%) N/A 6/2 3/1 3/1 2/0
Notes: Pre-Fev1 refers to mean change in prebronchodilator Fev1 at the end of the trial. Post-Fev1 refers to the mean change in postbronchodilator Fev1 at the end of the 
trial. SGRQ refers to change in mean St George Respiratory Question Score at the end of the treatment period. A reduction in score represents an improvement. Dropouts 
represent the percentage of patients that did not complete the treatment period. For each study, the first percentage represents the percentage of subjects in the roflumilast 
treatment arm that did not complete the study and the second percentage represents dropouts in the placebo arm. in each study, a greater percentage dropped out of the 
roflumilast treatment arms. The exacerbation rate refers to the number of moderate and severe exacerbations, exacerbation rate per patient, or the percentage of patients 
experiencing exacerbations during the study. In each case, the first number represents the roflumilast arm and the second the placebo arm of the studies. The next row 
contains the average difference in weight loss between the placebo arm and the treatment arms. In the three studies reporting weight loss, patients receiving roflumilast 
lost an average of slightly more than 2 kg more than the placebo-treated patients (N/A, data are not available). The last three rows represent the percentages of patients 
reporting diarrhea, nausea, and headache. In each case, the first percentage represents the percentage of patients reporting the side effect in the roflumilast arm and the 
second represents the percentage reporting the side effect in the placebo arm.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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headache.62–66,68 whereas the most prevalent adverse events 
were exacerbations of COPD and respiratory infections, fol-
lowed by GI symptoms including diarrhea, weight loss, and 
nausea. Weight loss is a concern in COPD patients, especially 
those with advanced disease who are often underweight. The 
weight loss averaged slightly more than 2 kg per patient 
and was greater in patients with GI symptoms and who 
had particularly severe COPD. Interestingly, there was an 
inverse relationship between the magnitude of the weight 
loss and body mass index; thin patients lost less weight than 
heavier ones. Although adverse events were more frequent in 
roflumilast-treated patients, serious adverse events generally 
were not more common (see below).62–66,68 ICS therapy has 
been a risk factor for developing pneumonia in some COPD 
clinical trials, but no evidence has emerged that this is more 
common in roflumilast-treated patients.72 The rates of atrial 
fibrillation were not increased with roflumilast.63
Neuropsychiatric adverse events were more common in 
patients who received 500 µg of roflumilast when compared 
with the lower 250 µg dose or placebo. Indeed, 403 (7%) 
adverse events were documented in the 5677 patients who 
received roflumilast (500 µg once daily) whereas only 190 
(3.5%) adverse events were reported in the 5491 patients 
who were given placebo (see www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/
Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/
UCM207377.pdf). In particular, the incidence of insom-
nia, anxiety, and depression was two to three times higher 
in the 500 µg roflumilast-treated group when compared 
with placebo. A potentially significant cause for concern 
was that of the 12054 patients in the roflumilast COPD 
database, three completed suicides (all in males) were 
reported in those patients given roflumilast compared 
with none in patients taking placebo. It is noteworthy 
that none of these individuals had a prior history of 
depression. There were also two suicide attempts (both 
in females). However, in these cases both individuals had 
prior psychiatric histories (see www.fda.gov/downloads/ 
AdvisoryCommittees/  CommitteesMeetingMaterials/
Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/
UCM207377.pdf).
Another potential serious adverse event was cancer. 
Analysis of the overall roflumilast clinical development pro-
gram revealed a total of 218 cancers/tumors in 208 patients. 
  Disproportionately more (n = 131, 60%) of these lesions 
were in the roflumilast-treatment group when compared with 
  placebo. Specifically, there was a greater incidence of lung and 
  prostate cancer reported in patients given roflumilast than in 
those individuals given placebo (see www.fda.gov/  downloads/
AdvisoryCommittees/  CommitteesMeetingMaterials/Drugs/
Pulmonary-  AllergyDrugsAdvisoryCommittee/UCM207377.
pdf). The significance of this observation is unclear. If 
  roflumilast is carcinogenic, one might expect a greater than 
one-year latency period before tumors develop. Indeed, 
  people smoke cigarettes for decades before they get lung 
cancer. Thus, the possibility that these findings are a chance 
observation, similar to the initial reports with omali-
zumab,73 rather than a response to treatment, should not be 
dismissed.
Contraindications, effects of food, 
and drug–drug interactions
No potential contraindications have, thus far, been identified 
in the roflumilast clinical development program. Although 
the metabolism of roflumilast is significantly arrested in 
patients with mild and moderate hepatic insufficiency, lead-
ing to increased systemic exposure (AUC0–24 = 51% and 92% 
higher in patients meeting Child-Pugh A and Child-Pugh B 
criteria, respectively, when compared with healthy subjects), 
changes to the pharmacokinetics of roflumilast N-oxide are 
relatively modest.74 Since the primary metabolite is believed 
to account for approximately 90% of the pharmacodynamic 
impact of roflumilast, the small pharmacokinetic changes 
reported are not believed to be clinically relevant. Thus, no 
dose adjustments are predicted to be required in patients with 
mild and moderate liver cirrhosis.74
Similarly, although a high-fat meal decreases Cmax and 
delays Tmax of roflumilast versus the fasted state, the same 
pharmacokinetic parameters are not changed for roflumilast 
N-oxide.75 Thus, because the primary metabolite mediates 
most of the pharmacologic effects of roflumilast, these data 
strongly suggest that the parent drug can be taken with or 
without food.
Many patients with COPD have multiple comorbidi-
ties which require other medications. The possibility that 
roflumilast and/or its N-oxide could interact unfavor-
ably with drugs commonly used in COPD has therefore 
been evaluated. Initial in vitro studies using human liver 
microsomes established that neither roflumilast nor roflu-
milast N-oxide inhibit CYP3A4, CYP1A2,76 CYP1A2, 
2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A5, or 4A9/11. 
Conversely, roflumilast does not induce CYP1A2, 2A6, 
2C9, 2C19, and 3A4/5, and is only a weak inducer of 
CYP2B6. Thus, there is a low potential for roflumilast to 
interact adversely with other drugs, including midazolam,76 
montelukast,77 budesonide,79 salbutamol,80 formoterol, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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warfarin, sildenafil, digoxin (see www.fda.gov/  downloads/
AdvisoryCommittees/  CommitteesMeetingMaterials/Drugs/
Pulmonary-  AllergyDrugsAdvisoryCommittee/UCM207377.
pdf), and antacids containing magnesium hydroxide/ 
aluminum hydroxide.60 This is important to determine 
because inducers of these enzymes have the potential to 
increase the clearance of roflumilast, thereby lowering its 
efficacy. Conversely, xenobiotics that are metabolized by 
the same enzyme(s) could compete with roflumilast, delay 
its inactivation, and so increase systemic exposure, with 
the potential for adverse events. However, rifampicin has 
been shown to limit the efficacy of roflumilast significantly 
due to its ability to induce enzymes that include CYP3A4, 
CYP2C19, and extrahepatic CYP1A2.58 Similarly, coadmin-
istration of erythromycin,78 ketoconazole,61 fluvoxamine, 
theophylline, cimetidine, enoxacin, and minulet significantly 
influence systemic exposure to roflumilast and the N-oxide 
(see www.fda.gov/downloads/AdvisoryCommittees/Com-
mitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrug-
sAdvisoryCommittee/UCM207377.pdf).
Polyaromatic hydrocarbons, which are constituents 
of cigarette smoke, are known to induce CYP1A1 and 
CYP1A2.81–83 Although CYP1A2 contributes to roflumilast 
metabolism and may enhance the rate at which the N-oxide is 
produced in cigarette smokers (see above), the N-oxide is not 
a substrate for CYP1A2.74 Accordingly, no dose adjustments 
are likely to be required in smoking patients with COPD.
Positioning roflumilast in clinical 
management of COPD
There are insufficient data to recommend the use of   roflumilast 
in patients with mild COPD. The clinical   trials with   roflumilast 
have been conducted in patients with   moderate or severe 
COPD.62–66,68 Roflumilast improved lung function in patients 
with more severe COPD,   especially in those with chronic 
bronchitis, those with recent   exacerbations, and those requir-
ing frequent rescue inhaler use, whether given alone or in 
combination with the long-acting bronchodilators, salmeterol 
or tiotropium.62–66,68 In these patients, roflumilast also reduced 
exacerbations when given alone or in combination with long-
acting bronchodilators. No studies have addressed whether 
roflumilast might supplant ICSs in combinations with long-
acting bronchodilators or whether there is a benefit to adding 
it to combinations of ICSs and long-acting bronchodilators.
Although the studies reviewed herein were done in dif-
ferent COPD populations adhering to different protocols, the 
reported results with roflumilast are similar to the outcome in 
patients with COPD of similar severity treated with ICSs.66 In 
the TORCH (Towards a Revolution in COPD Health) study, 
postbronchodilator FEV1 declined 47 mL less per year in 
patients treated with fluticasone propionate compared with 
placebo-treated patients.66 In the roflumilast studies, post-
bronchodilator FEV1 declined 39 mL, 49 mL, and 61 mL less 
in roflumilast-treated compared with placebo-treated patients 
over the one year of the study.63,65 In the TORCH study, 
postbronchodilator FEV1 was 50 mL/year in patients treated 
with salmeterol-fluticasone compared with those treated with 
salmeterol alone.66 Postbronchodilator FEV1 was 60 mL 
greater in patients treated with the combination of roflumilast 
and salmeterol for one year compared with patients treated 
with salmeterol alone.68 The combined moderate and severe 
exacerbation rate was reduced 18% in ICS-treated patients 
compared with placebo in the TORCH study.66 In comparison, 
the exacerbation rate was reduced 17% in the roflumilast-
treated group compared with placebo.65
The optimal placement of roflumilast in the treatment 
algorithm remains uncertain. Possible indications include 
patients with more severe COPD who remain inadequately 
controlled despite the use of combination therapy. In the 
absence of sufficient clinical trial data, potential positioning 
in the treatment algorithm include use in patients inadequately 
controlled on a combination of LAAC and LABA and use 
in patients inadequately controlled with a LAAC, LABA, 
and ICS or where theophylline is generally used. Important 
advantages are that it avoids many drug interactions, narrow 
therapeutic index of theophylline, and the need for regular 
blood level monitoring.38 Potential disadvantages are that it is 
not a bronchodilator, lacks the clinical track record of a drug 
used for over 70 years, and the cost of a new drug versus an 
older generic medication.
Compared with ICSs, a potential advantage of combining 
roflumilast with long-acting bronchodilators is the ease of taking 
a pill once daily rather than having to be able to use an inhaler 
properly, and which needs to be taken twice daily. Roflumi-
last is not related to an increased risk of pneumonia or other 
adverse affects associated with ICSs use, such as osteoporosis, 
glaucoma, cataracts, and skin thinning. However, roflumilast 
is associated with other adverse effects, including weight loss 
and a greater risk of discontinuation of therapy whether given 
alone, or with short- and/or long-acting bronchodilators.62–66,68 
Moreover, serious adverse events include an apparently higher 
incidence of neuropsychiatric abnormalities and of certain 
cancers. In this respect, it is salient that in January 2010 For-
est Laboratories submitted to the FDA a new indication for 
roflumilast together with associated labeling changes and 
a warning regarding neuropsychiatric events. The revised Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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indication for roflumilast is for the “maintenance treatment 
of chronic obstructive pulmonary disease (COPD) associated 
with chronic bronchitis in patients at risk of exacerbations” 
and is more restrictive than broad maintenance treatment 
of COPD (www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugs 
AdvisoryCommittee/UCM207377.pdf). In April 2010, the 
Pulmonary-Allergy Drugs Advisory Committee (PADAC) con-
vened by the FDA voted by 10 votes to five against approving 
roflumilast for the treatment of COPD (www.medscape.com/
viewarticle/720010). Although the PADAC believe roflumi-
last to be safe and modestly effective, it seems likely that this 
negative outcome reflects a concern that the potential adverse 
events outweigh the modest improvements in lung function. 
However, on 22 April 2010, the European Medicines Agency 
Committee for Medicinal Products for Human Use adopted an 
opposite stance to PADAC and recommended the granting of a 
marketing authorization for roflumilast. The approved indication 
is for the “… maintenance treatment of severe chronic obstruc-
tive pulmonary disease (COPD, FEV1 post-bronchodilator less 
than 50% predicted) associated with chronic bronchitis in adult 
patients with a history of frequent exacerbations as add-on to 
bronchodilator treatment” (www.ema.europa.eu/pdfs/human/
opinion/Daxas_15986110en.pdf). A final decision by the FDA 
is expected in May 2010 after negotiations with Forest. Regard-
less of the outcome of those talks, in the   European Union at 
least, after more than 20 years of development, roflumilast will 
become the first class PDE4 inhibitor for the treatment of COPD 
and will provide physicians with another treatment option for 
patients with more severe disease.
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